Nadia Lybøl von Schoubye, Ph.D. - Publications
Affiliations: | 2022- | CNS Diseases | Boehringer Ingelheim Pharma GmbH & Co. KG |
Area:
CNS Drug DiscoveryYear | Citation | Score | |||
---|---|---|---|---|---|
2017 | von Schoubye NL, Frederiksen K, Kristiansen U, Petersen AV, Dalby NO, Grunnet M, Jensen HS, Jespersen T, Sohal VS, Perrier JF. The sodium channel activator Lu AE98134 normalizes the altered firing properties of fast spiking interneurons in Dlx5/6(+/-) mice. Neuroscience Letters. PMID 28987817 DOI: 10.1016/J.Neulet.2017.10.004 | 0.565 | |||
2017 | Simonsen C, Boddum K, von Schoubye NL, Kloppenburg A, Sønderskov K, Hansen SL, Kristiansen U. Anticonvulsive evaluation of THIP in the murine pentylenetetrazole kindling model: lack of anticonvulsive effect of THIP despite functional δ-subunit-containing GABAA receptors in dentate gyrus granule cells. Pharmacology Research & Perspectives. 5. PMID 28805971 DOI: 10.1002/Prp2.322 | 0.545 | |||
2017 | Boddum K, Hougaard C, Xiao-Ying Lin J, von Schoubye NL, Jensen HS, Grunnet M, Jespersen T. Kv3.1/Kv3.2 channel positive modulators enable faster activating kinetics and increase firing frequency in fast-spiking GABAergic interneurons. Neuropharmacology. 118: 102-112. PMID 28242439 DOI: 10.1016/j.neuropharm.2017.02.024 | 0.64 | |||
2015 | Taskin B, von Schoubye NL, Sheykhzade M, Bastlund JF, Grunnet M, Jespersen T. Biophysical characterization of KV3.1 potassium channel activating compounds. European Journal of Pharmacology. 758: 164-70. PMID 25845309 DOI: 10.1016/J.Ejphar.2015.03.061 | 0.613 | |||
Show low-probability matches. |